Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
about
Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States.Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US.Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasisHealth Resource Utilization Associated with Skeletal-Related Events in Patients with Advanced Prostate Cancer: A European Subgroup Analysis from an Observational, Multinational Study.Exploiting machine learning for predicting skeletal-related events in cancer patients with bone metastases.Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.Hypercalcaemia and hypocalcaemia: finding the balance.Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint.The role of the microenvironment-dormant prostate disseminated tumor cells in the bone marrow.The biology and clinical implications of prostate cancer dormancy and metastasis.Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy.Thermotherapy using magnetic cationic liposomes powerfully suppresses prostate cancer bone metastasis in a novel rat model.RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model.Healthcare-resource utilization associated with radiation to bone across eight European countries: Results from a retrospective study.
P2860
Q33599987-63844A31-4F3A-4A73-ABEF-4C6212F786DAQ35161962-27F4CEA2-CB43-45AB-A3D3-75AA748555D4Q35345620-1F18B44A-EEA2-4C5F-9A05-CA5C2B83EB19Q35667133-92DA114B-FAA4-4C21-865C-0152C954073CQ37022238-5F8A7DFF-1D53-4937-8811-386B52CEF9A5Q37669384-3C23BD75-44AC-4E02-9A35-ECE102B277A1Q37736066-DC694E2A-7602-4243-9058-0D048E0BF5B9Q38069186-D8268F23-30BD-4206-9080-5EAA8267BF28Q38213416-4A69D965-40D8-4BB5-809E-493E741423C6Q38613304-536259FB-E60B-46E5-9E8B-17B2CB1652B6Q38766102-ADB5523B-8308-46DC-A232-5B478AAA50FAQ39952307-2601FB72-7A5D-4D7D-B520-76157A8D2981Q43026697-57632B99-D60F-410B-8017-2936D08DB2B3Q44486633-8E8201D3-95E9-4AEB-A352-A858988C53E5Q46715452-E1549595-F334-460E-A848-7C7A2BD104BEQ54941803-65B8B27D-26ED-411A-8812-4586A565F229
P2860
Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Rationale for zoledronic acid ...... th or without bone metastasis.
@ast
Rationale for zoledronic acid ...... th or without bone metastasis.
@en
type
label
Rationale for zoledronic acid ...... th or without bone metastasis.
@ast
Rationale for zoledronic acid ...... th or without bone metastasis.
@en
prefLabel
Rationale for zoledronic acid ...... th or without bone metastasis.
@ast
Rationale for zoledronic acid ...... th or without bone metastasis.
@en
P2093
P1433
P1476
Rationale for zoledronic acid ...... th or without bone metastasis.
@en
P2093
James Eastham
James McKiernan
P356
10.1016/J.UROLONC.2005.06.020
P577
2006-01-01T00:00:00Z